



2024 American Society of Clinical Oncology (ASCO) Annual Meeting

TAKEDA ONCOLOGY
SPONSORED ABSTRACTS

 @TakedaOncology

Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2024 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY

| ABSTRACT # | TITLE | SESSION |
|------------|-------|---------|
|------------|-------|---------|

HODGKIN LYMPHOMA

[ABSTRACT 7000](#)

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study

ORAL PRESENTATION

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Saturday, June 1, 2024
3:00–6:00 PM CDT

Location: S100bc



[ABSTRACT 7053](#)

Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma

POSTER PRESENTATION

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Monday, June 3, 2024
9:00 AM–12:00 PM CDT

Location: Hall A



METASTATIC COLORECTAL CANCER (mCRC)

[ABSTRACT 3507](#)

Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis

ORAL PRESENTATION

Gastrointestinal Cancer: Colorectal and Anal

Sunday, June 2, 2024
8:00–11:00 AM CDT

Location: Arie Crown Theater



[ABSTRACT 3579](#)

Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2

POSTER PRESENTATION

Gastrointestinal Cancer—Colorectal and Anal

Saturday, June 1, 2024
1:30–4:30 PM CDT

Location: Hall A



NON-SMALL CELL LUNG CANCER (NSCLC)

[ABSTRACT 1107](#)

Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care

POSTER PRESENTATION

Quality Care/Health Services Research

Monday, June 3, 2024
9:00 AM–12:00 PM CDT

Location: Hall A



LEUKEMIAS

[ABSTRACT 6501](#)

Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

ORAL POSTER PRESENTATION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Friday, May 31, 2024
2:45–5:45 PM CDT

Location: S100bc



[ABSTRACT 6533](#)

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL

POSTER PRESENTATION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Monday, June 3, 2024
9:00 AM–12:00 PM CDT

Location: Hall A



VV-MEDMAT-104858, May 2024

TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited.

CERTAIN OF THESE ABSTRACTS MAY RELATE TO DRUGS AND/OR USES THAT ARE INVESTIGATIONAL, AND FOR WHICH SAFETY AND EFFICACY HAVE NOT YET BEEN ESTABLISHED. THIS IS NO GUARANTEE THAT SUCH DRUGS AND/OR USES WILL BE APPROVED.



ONCOLOGY

ABSTRACT #

TITLE

SESSION

PIPELINE

[ABSTRACT TPS2684](#)

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3 ϵ Conditional Bispecific Redirected Activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors

POSTER PRESENTATION

Developmental Therapeutics—
Immunotherapy

Saturday, June 1, 2024
9:00 AM-12:00 PM CDT

Location: Hall A



[ABSTRACT 2543](#)

Updated results from first-in-human Phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors

POSTER PRESENTATION

Developmental Therapeutics—
Immunotherapy

Saturday, June 1, 2024
9:00 AM-12:00 PM CDT

Location: Hall A



For more information, please see [ASCO online program](#).

VV-MEDMAT-104858, May 2024

TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited.

CERTAIN OF THESE ABSTRACTS MAY RELATE TO DRUGS AND/OR USES THAT ARE INVESTIGATIONAL, AND FOR WHICH SAFETY AND EFFICACY HAVE NOT YET BEEN ESTABLISHED. THIS IS NO GUARANTEE THAT SUCH DRUGS AND/OR USES WILL BE APPROVED.



ONCOLOGY